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ABSTRACT
GRK2 is a member of the G protein-coupled receptor kinase family
that phosphorylates the activated form of b-adrenergic and other G
protein-coupled receptors and plays an important role in their de-
sensitization and modulation. Alterations in thyroid hormone levels
have been reported to lead to important changes in adrenergic re-
ceptor responsiveness and signaling in a variety of tissues. In this
context, we have explored the effects of experimental hypothyroidism
on GRK2 protein levels in rat heart, lung, and liver using a specific
antibody. Hypothyroid animals show significant up-regulation (.50%
increase compared with controls) in GRK2 levels in heart and lung at
60 days after birth, whereas a 50% reduction is detected in the liver
at this stage. These alterations are selective, as b-adrenergic recep-
tors or other G protein-coupled receptor regulatory proteins, such as
G protein-coupled receptor kinase 5 or b-arrestin-1, display a differ-
ent pattern of expression changes in the hypothyroid animals. The
reported changes in GRK2 levels and in the receptor/kinase ratio
predict alterations in adrenergic receptor desensitization and signal
transduction efficacy consistent with those observed in thyroid dis-
orders, thus suggesting a relevant role for the modulation of GRK2
expression in this physiopathological condition. (Endocrinology 142:
987–991, 2001)
THE ADRENERGIC system and thyroid hormones inter-act physiologically in a coordinated manner. In a va-
riety of tissues, thyroid hormones enhance the b-adrenergic
receptor (bAR)-mediated actions of catecholamines by in-
creasing the accumulation of cAMP by mechanisms acting at
both the receptor and postreceptor levels as well as by en-
hancing the transcriptional effects of cAMP. Hypothyroid-
ism severely reduces the b-adrenergic response in most tis-
sues, contributing to the development of cardiovascular
dysfunction, altered metabolic responses, and decreased
thermogenesis (1–4). Thyroid hormone deficit appears to
promote such impaired responsiveness or sensitivity to cat-
echolamines by reducing the number of bAR and increasing
the number of a-adrenergic receptors. However, additional
mechanisms are needed to explain the overall effect of hy-
pothyroidism on adrenergic signal transduction (4).
Receptors for cathecolamines belong to the G protein-
coupled receptor (GPCR) family. G protein-coupled receptor
kinases (GRKs) are a family of serine-threonine kinases that
specifically phosphorylate the agonist-occupied form of
GPCR. This is followed by binding to the phosphorylated
receptor of members of a second family of proteins, termed
b-arrestins, leading to receptor uncoupling from heterotri-
meric G proteins and signal shut off. This process is known
as desensitization, a general feature of GPCR signaling that
involves a loss of receptor responsiveness after acute or sus-
tained activation. GRK2 is one of the more abundant and
broadly expressed GRKs that has been shown to participate
in the regulation of adrenergic receptors and many other
GPCRs (5–7). Interestingly, changes in the expression levels
of GRK2 have been suggested to underlie alterations in ad-
renergic receptor signaling and desensitization in several
physiopathological situations, such as heart failure, hyper-
tension, experimental models of cardiac hypertrophy, or neo-
natal stress (7–13). In this context, we have explored the
consequences of experimentally induced hypothyroidism on
the protein expression levels of GRK2 at two developmental
stages in several rat tissues (liver, heart, and lung) markedly
affected by thyroid hormone deficit. We have also explored
the expression levels of b-adrenergic receptors; of GRK5, a
member of the GRK family that modulates a variety of GPCR
in the cardiovascular system (5, 6); and of b-arrestin-1, a
ubiquitous member of the b-arrestin regulatory family. Our
data indicate that hypothyroidism promotes significant and
specific alterations in GRK2 levels in these tissues that may
contribute to the previously reported changes in adrenergic
receptor signaling in such pathological situations.
Materials and Methods
Animal treatment
Wistar rats raised in our animal facilities were used, and the rules of
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86/609/ECC) concerning the maintenance and handling of animals
were followed. Hypothyroidism was induced by a combination of chem-
ical and surgical thyroidectomies, as previously described (14). To
induce neonatal hypothyroidism, dams were given 0.02% methyl-
mercaptoimidazol (Sigma, St. Louis, MO) in their drinking water from
the ninth day after conception. Hypothyroidism in adult rats was in-
duced by thyroidectomy at postnatal day 40 followed by 20 days of
methyl-mercaptoimidazol treatment. Animals were killed at different
postnatal ages by decapitation. Various tissues (lungs, hearts, and livers)
were removed and frozen at 270 C until used.
Determination of GRK2, GRK5, and b-arrestin-1
protein levels
Rat tissues were homogenized using a Polytron device (Brinkmann
Instruments, Inc., Westbury, NY) in 4 vol 20 mm Tris-HCl (pH 7.5), 5 mm
EDTA, 5 mm EGTA, and protein inhibitors (buffer A). The homogenate
was centrifuged (1500 3 g, 5 min, 4 C) to obtain a crude postnuclear
supernatant. Aliquots of these lysates containing 100 mg protein were
resolved in 7.5% or 10% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes for 60–75 min in 10 mm NaHCO3, 3 mm
Na2CO3 (pH 10), and 20% methanol using a Transblot cell (Bio-Rad
Laboratories, Inc., Richmond, CA). The filters were blocked with 10 mm
Tris-HCl (pH 7.5)/150 mm NaCl and 5% fat-free dried milk. GRK2
protein was detected with AbFP1, a polyclonal antibody raised against
a fusion protein containing amino acids 50–145 of bovine GRK2, the
specificity of which has been previously validated (15, 16). GRK5 protein
levels were determined using both a commercially available affinity-
purified antibody [GRK5 (C-20), Santa Cruz Biotechnology, Inc., Santa
Cruz, CA; dilution, 1:100] as well as a polyclonal antibody (Ab9) raised
against recombinant GRK2 protein (13) that displays cross-reactivity
with GRK5 (dilution, 1:1000). b-Arrestin-1 expression was analyzed with
Ab186, a polyclonal antibody raised in our laboratory against a fusion
protein containing amino acids 172–268 of bovine b-arrestin-1 that spe-
cifically recognizes this arrestin isoform (17, 18). Blots were developed
using a chemiluminescent method (ECL, Amersham Pharmacia Biotech,
Arlington Heights, IL) after incubation with a goat antirabbit antibody
conjugated to peroxidase.
Radioligand binding assay of b-adrenergic receptors
Rat tissues were homogenized with a Polytron device (three times, 30
sec each time) in 10 vol buffer A. The supernatant of a low speed
centrifugation (2,000 3 g, 4 min, 4 C) was centrifuged at 45,000 3 g for
20 min at 4 C to obtain a plasma membrane pellet. Membranes were
washed three times in buffer A and finally resuspended in the same
buffer at concentrations of 3–10 mg protein/ml. Total bAR number was
determined as previously reported (13), using 5 nm [3H]dihydroalpre-
nolol (Amersham Pharmacia Biotech) and 100 mm (2)propanolol to
define nonspecific binding. b1AR and b2AR levels were estimated using
1 mm alprenolol as a specific b1AR competitor. At least three different
tissue samples from pools of three or four control or hypothyroid rats
were employed for each binding determination; determinations were
performed in triplicate.
Results and Discussion
To test the effect of hypothyroidism on GRK2 expression
levels, we performed immunoblot analysis using extracts
from selected rat tissues of normal and hypothyroid animals
obtained at two different postnatal ages and a specific kinase
antibody. In the heart, the normal developmental pattern of
FIG. 1. Protein levels of GRK2 in heart, lung, and liver of euthyroid
and hypothyroid rats at different stages of postnatal development.
Extracts from the indicated rat tissues (three independent pools of
five or six animals) were obtained at two different postnatal ages from
euthyroid and hypothyroid rats, as indicated in Materials and Meth-
ods. Proteins (100 mg/lane) were resolved by electrophoresis on 10%
SDS-polyacrylamide gels, blotted to a nitrocellulose membrane, and
probed with a specific antibody raised against GRK2 (AbFP1; dilu-
tion, 1:1000) as indicated in Materials and Methods, followed by
densitometric analysis of the specific GRK2 bands. Expression levels
in control conditions at each postnatal age are taken as 100%. Data
are the mean 6 SEM of six determinations. **, P , 0.01; ***, P , 0.0001
(compared with levels under euthyroid conditions at the correspond-
ing age). M, Control condition; f, hypothyroid condition. Represen-
tative immunoblots are shown below.
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GRK2 expression is characterized by high levels at birth,
followed by a sustained diminution until adulthood (Penela,
P., unpublished data). Comparison of GRK2 immunoreac-
tivity in the hearts of control and hypothyroid animals in-
dicates that thyroid hormone deficiency significantly in-
creases (;1.5-fold compared with euthyroid animals) the
expression of GRK2 at 60 days after birth, whereas the GRK2
expression levels attained on postnatal day 5 were similar in
control and hypothyroid rats (Fig. 1). A significant increase
in GRK5 protein levels was also observed in the heart of
hypothyroid animals at 60 days after birth (Fig. 2), whereas
the expression of the uncoupling protein b-arrestin-1 was not
altered at 5 or 60 days of postnatal development in the treated
animals (Fig. 3).
Alterations in the cellular complement of GRK2 and in the
receptor/kinase ratio have been reported to affect GPCR
desensitization and signaling (5, 6). Namely, changes in the
balance between b-adrenergic receptors and GRK2 levels
have been proved relevant in cardiac receptor signaling. The
positive cronotropic and inotropic effects triggered by cat-
echolamines on cardiac function are modulated by kinase
levels; they are decreased or enhanced in transgenic animals
overexpressing either GRK2 or a GRK2 inhibitory construct,
respectively (19). Moreover, the extent of contractility and
sensitivity to b-agonists was inversely related to GRK2 ac-
tivity in genetically modified mice with different levels of
kinase expression (20), and, interestingly, reduction of GRK2
activity in a genetic model of murine heart failure can restore
normal cardiac function (11). The extent of change in GRK2
levels in hypothyroid rat heart is in the same range as that
observed in other physiopathological situations, such as in
human heart failure (9), in cerebral cortex or locus coeruleus
after opiate treatment (16), or in circulating lymphocytes of
hypertensive patients (10), thus suggesting that such changes
might be physiologically relevant.
Increased GRK2 levels, as detected in the hearts of hypo-
thyroid rats, would be predicted to impair b-adrenergic re-
ceptor signaling. Interestingly, we found that both b1AR and
b2AR levels are decreased at 60 days after birth in the hy-
pothyroid rat heart (b1AR, 32.2 6 2.3 fmol/mg protein in
control animals and 15.8 6 6.5 fmol/mg protein in treated
animals; b2AR, 12.1 6 6.4 fmol/mg protein in control rats
and 7.6 6 3.6 fmol/mg protein in hypothyroid animals;
mean 6 sem of three to five independent experiments). It has
been previously reported that bARs are markedly down-
regulated in hypothyroid conditions (21–23), and that the
sensitivity of cardiac cells to b-agonist stimulation is de-
creased, particularly at high concentrations of agonist (21).
Thus, hypothyroidism appears to simultaneously promote a
reduction in bAR density and an increase in GRK2 levels,
leading to marked alterations in the receptor/GRK2 ratio
and therefore to increased desensitization and impaired sig-
naling of the remaining receptors. This situation is similar to
that taking place in heart failure patients, where b1AR re-
duction and increased GRK2 levels promote marked receptor
desensitization and increased sympathetic tone (9, 24). In
fact, similar alterations in catecholamine signaling and an
increase in cardiac efferent sympathetic activity have also
been reported as a consequence of T3 deficiency (3). The fact
that GRK5, a member of the GRK family involved in the
modulation of GPCR present in cardiovascular cells (5, 6),
also displays increased levels of expression in the hypothy-
roid rat heart would further lead to a decreased signaling
mediated by b-adrenergic and other GPCR in these circum-
stances. In summary, our data strongly suggest that the in-
creased levels of GRKs in hypothyroid heart would contrib-
ute to the impairment of adrenergic responsiveness and
cardiac function reported in such pathological situations.
Similar changes in GRK2 levels are also detected in the
FIG. 2. Protein levels of GRK5 in adult heart and lung of euthyroid
and hypothyroid rats. Tissue samples were obtained as described in
Fig. 1, and proteins (75 mg/lane) were resolved by electrophoresis on
7.5% SDS-polyacrylamide gels. GRK5 expression was investigated by
immunoblot as indicated in Materials and Methods, followed by den-
sitometric analysis. The expression level in control conditions was
taken as 100%. Data are the mean 6 SEM of four to seven determi-
nations. **, P , 0.01 compared with control levels. Representative
immunoblots are shown. M, Control condition; f, hypothyroid con-
dition.
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lung of hypothyroid rats at 60 days alter birth (Fig. 1). At this
postnatal stage we do not detect significant changes in bAR
levels in the hypothyroid rat lung (data not shown), although
a previous study reported diminished bAR expression in the
hypothyroid rats at 28 days of age (25). Overall, these data
indicate that in the adult rat lung, T3 deficiency modifies the
normal pulmonary balance between bARs and their regu-
latory protein GRK2. Given that the expression level of this
kinase has been correlated to the extent of b-agonist-
promoted desensitization in different pulmonary cell types
(26), our findings suggest that the observed changes in GRK2
levels may indeed result in alterations of receptor function
that may contribute to the impairments of surfactant release
and smooth muscle relaxation commonly associated with
thyroid disorders (4).
A different effect of thyroid hormone deficit on GRK2
levels is observed in the liver. In this tissue, GRK2 levels at
birth are markedly high compared with adult values in con-
trol animals (13) (Penela, P., unpublished observations), and
no GRK5 immunoreactivity is detected (not shown). Hypo-
thyroidism appears to promote a further decrease in GRK2
immunoreactivity at 60 days of life (Fig. 1). At this stage, a
significant, approximately 2-fold reduction in GRK2 expres-
sion is observed in hypothyroid rats. Such a decrease in
GRK2 levels would be predicted to relieve GPCR desensiti-
zation, thus increasing responsiveness to agonists. Consis-
tently, hypothyroidism has been shown to potentiate, rather
than reduce, catecholamine action in this tissue compared
with that in heart or lung. This effect was ascribed to a
specific increase in bAR number that would result in a pref-
erential b-agonist stimulation of gluconeogenesis and gly-
cogenolysis (27–29), although there are controversial data on
the effect of hypothyroidism in rat liver bARs depending on
the rat strain and the methods of induction of hypothyroid-
ism and radioligand binding employed (27, 30). In our hands,
b1AR levels were decreased (;3-fold) and b2AR number was
increased (;3.5-fold) in the hypothyroid rat liver (data not
shown), consistent with the important role of b2AR in me-
diating the actions of adrenaline in the liver under certain
physiological conditions (31, 32). Hypothyroidism also pro-
motes an improvement in bAR coupling that cannot be as-
cribed to changes in adenylyl cyclase or Gs protein (7, 33, 34)
and that could be explained by our reported changes in
GRK2 expression. Interestingly, signaling through other
GPCRs that play an essential role in hepatic metabolism, such
as receptors for vasopressin or angiotensin II, is also altered
in hypothyroid animals (35). Agonist stimulation of these
receptors leads to a second messenger response similar to
that of euthyroid controls despite the reduced number of
receptors in such a condition, thus suggesting a better cou-
pling of receptors to the transduction machinery, which
would be favored by reduced GRK2 levels.
The observed changes in b-arrestin-1 expression in lung
and liver are opposed to those found for GRK2 levels in these
tissues, confirming an independent regulation of the expres-
are taken as 100%. Data are the mean 6 SEM of at least six deter-
minations. **, P , 0.01 compared with levels under control conditions
at the corresponding age. M, Control condition; f, hypothyroid con-
dition. Representative immunoblots are shown below.
FIG. 3. Effects of hypothyroidism on b-arrestin-1 protein levels in rat
heart, lung, and liver at different stages of postnatal development.
Samples were obtained as described in Fig. 1, and proteins (100
mg/lane) were resolved by electrophoresis on 10% SDS-polyacryl-
amide gels. b-Arrestin-1 levels were analyzed with a specific poly-
clonal antibody (Ab186; dilution, 1:600) as detailed in Materials and
Methods. Expression levels in control conditions at each postnatal age
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sion of these proteins and suggesting the occurrence of com-
pensatory mechanisms. However, the potential functional
correlates of these changes in b-arrestin-1 levels in the hy-
pothyroid animals are more difficult to discuss, given the fact
that this protein acts downstream of GRK2 in GPCR regu-
lation and that each b-arrestin isoform can display different
affinities for activated GPCR (for instance, b-arrestin-1 bind-
ing to b1AR is weaker than that to b2AR) (36). More detailed
studies will be needed to ascertain how the combined
changes in GRK and b-arrestin expression in a given tissue
or cell type affect the function of specific GPCRs in
hypothyroidism.
In summary, we found that experimental hypothyroidism
leads to selective changes in GRK2 expression in several rat
tissues, thus suggesting that thyroid hormones are able to
directly or indirectly regulate GRK2 protein levels in a tissue-
specific manner by mechanisms that need to be addressed in
future studies. The observed changes in GRK2 levels in hy-
pothyroid animals are strikingly correlated with previously
reported changes in adrenergic signaling in this physio-
pathological condition. Our results suggest that even modest
expression changes at the levels of both GPCR and their
regulatory protein GRK2 would lead to significant alter-
ations of the receptor/GRK2 ratio in hypothyroidism and
may contribute to a better understanding of the impairment
of b-adrenergic and GPCR signaling that underlies thyroid
disorders.
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